Haloperidol is the most widely used antipsychotic drug in the treatment of psychiatric disorders. Despite its satisfactory therapeutic effect, its chronic use is related to severe motor side effects. Here, we investigate the incidence of motor side effects of haloperidol-loaded nanocapsules when compared to free haloperidol and the relation with oxidative stress (OS) development. Both vehicle (B-NcFO) and haloperidol loaded polysorbate-coated nanocapsules suspension (H-NcFO) prepared with fish oil as core showed uniform and rounded particles, nanometric size, negative zeta potential, low polydispersity indices and high encapsulation efficiency. Wistar rats received a single dose of free haloperidol (FH), B-NcFO or H-NcFO (0.2 mg/kg ip) and were submitted to acute motor side effects evaluation 1 h after the injection. Lower catalepsy time and oral dyskinesia were observed in H-NcFO-treated group than in FH group; however, both formulations decreased animals' locomotor activity. In a experiment performed subchronically, rats injected daily with H-NcFO (0.2 mg/kg-ip) for 28 days showed decreased oral dyskinesia frequency and catalepsy time and no impairment on locomotor activity as compared to FH group (0.2 mg/kg-ip). FH group showed higher OS, as observed by increased lipid peroxidation and reduced glutathione levels and catalase activity in extrapyramidal region. Our findings showed that nanocapsules may be an efficient form to prevent or minimize haloperidol motor side effects, which are related to OS development, ameliorating psychiatric patients' quality of life.
Introduction
Haloperidol is a typical antipsychotic drug used in the treatment of schizophrenia, mania and neurological disorders and recognized for its potency, specificity and long action (Mutschler et al., 1995) . Its mechanism of action is mediated by blockade of D2 dopamine receptors in brain (Creese et al., 1996) .
The antipsychotic efficacy of haloperidol is somewhat compromised by the tendency to cause acute and chronic extrapyramidal movement disorders such as parkinsonism, akathisia, dystonias, and tardive dyskinesia, which is characterized by repetitive, often irreversible and disabling involuntary movements (Andreassen and Jorgensen, 2000) . Haloperidol and its metabolites also produce abnormal movements in animals, e.g., oral dyskinesia (OD), which has been associated with morphological alterations and oxidative stress (OS) in extrapyramidal brain regions (Andreassen and Jorgensen, 2000; Burger et al., 2006; Fachinetto et al., 2007; Naidu et al., 2003) . In this sense, the pathophysiology of movement disorders induced by haloperidol has been related to oxidative damage (Burger et al., 2006 (Burger et al., , 2005a and neurotoxicity, which are closely related to increase of turnover rate of dopamine (by blockade of presynaptic receptors), leading to production of reactive substances as a by-product of its metabolism (Andreassen and 0197-0186 Ó 2012 Elsevier Ltd. http://dx.doi.org/10.1016/j.neuint.2012.06.015
Abbreviations: BBB, blood-brain barrier; B-NcFO, blank polysorbate-coated nanocapsules suspension; CAT, catalase; FH, free haloperidol; FO, fish oil; GSH, reduced glutathione; H-NcFO, haloperidol loaded polysorbate-coated nanocapsules suspension; ip, intraperitoneal; LP, lipid peroxidation; MDA, malondialdehyde; OD, oral dyskinesia; OS, oxidative stress; TBARS, thiobarbituric acid reactive species; TEM, transmission electron microscopy; VCM, vacuous chewing movement. Jorgensen, 2000) . Furthermore, the brain is more susceptible to oxidative damage when compared to other organs or systems (Halliwel and Gutteridge 1999) , mainly because it contains high levels of membrane lipids, excitotoxic amino acids, low levels of antioxidant defenses, and autoxidizable neurotransmitters. Experimentally, several studies conducted in our laboratory have shown a relationship between haloperidol-induced movement disorders and OS, as well as beneficial effects of antioxidant compounds (Barcelos et al., 2010; Burger et al., 2006 Burger et al., , 2005a Colpo et al., 2007; Trevizol et al., 2011) .
Although more recent atypical neuroleptics do not cause extrapyramidal motor disorders, their clinical use remains restricted to a minority of patients because of their high cost, body weight gain, and development of diabetes and blood dyscrasias requiring intensive monitoring (Meltzer et al., 1995) . For these reasons, typical neuroleptics such as haloperidol are still the most widely used antipsychotic drugs in treatment of schizophrenia and other psychiatric disorders (Ponto et al., 2000) .
Polymeric nanoparticles have attracted considerable attention as potential drug delivery systems, increasing therapeutic efficacy and reducing side effects of a variety of drugs associated with these systems (Beck et al., 2005 (Beck et al., , 2006 Bernardi et al., 2009; Mora-Huertas et al., 2010) . Polymeric nanoparticles present a size ranging from 10 to 1000 nm and are employed to carry drugs by incorporation or absorption (Garcia-Garcia et al., 2005) . Carried by nanoparticles, drugs can be released at controlled rates and to specific body sites to obtain accurate delivery, which will enhance their therapeutic efficacy and reduce their toxicity and side effects (Kreuter et al., 2002; Mohanraj and Chen, 2006) .
Polysorbate-coated nanoparticles were previously reported as efficient carriers capable of transporting the loaded drugs across blood-brain barrier (BBB) after administration, being interesting drug delivery systems to the brain (Bernardi et al., , 2009 Xin-Hua et al., 2011; Wang et al., 2009) . Furthermore, polymeric nanoparticles can be used as parenteral controlled release systems to prolong the availability of drugs that freely penetrate the BBB but have a short duration of action in the central nervous system (Friese et al., 2000) .
It was demonstrated that the association of antipsychotic risperidone with nanoparticles prolonged its therapeutic effect and reduced catalepsy time in mice (Muthu and Singh, 2008; Muthu et al., 2009 ). Recently we reported better therapeutic efficacy and longer time of action by haloperidol nanocapsules in a pseudo-psychosis animal model . Moreover, this formulation also caused minor acute and subchronic extrapyramidal side effects, as observed by reduction of OD and shorter time of catalepsy in rats. In addition, since extrapyramidal motor side-effects are related to haloperidol treatment, in the present study we aimed to observe the acute and subchronic motor side effects induced by free and nanoencapsulated haloperidol and their relationship to OS markers in dopaminergic brain regions involved in the development of movement disorders. For this, we developed haloperidolloaded polysorbate-coated nanocapsules containing fish oil (FO) rich in n-3 fatty acids, whose antiapoptotic actions (Bazan, 2007) have shown beneficial effects in animal models of movement disorders (Barcelos et al., , 2010 We hypothesized that this haloperidol nanoformulation may be an alternative to overcome some drawbacks associated with the therapeutic use of free haloperidol.
Materials and methods

Chemicals
Haloperidol was obtained from Galena (Campinas-SP, Brazil). Fish oil capsules (Achè-Guarulhos-SP, Brazil), containing 1 g oil/ capsule with 120 mg of DHA and 180 mg of EPA were used. Poly(e-caprolactone) and sorbitan monostearate (Span 60 Ò ) were obtained from Sigma (Tatuapé-SP, Brazil). Polysorbate 80 was acquired from Delaware (Porto Alegre, RS, Brazil). All other chemicals and solvents used were of pharmaceutical or HPLC grade and used as received.
Animals
Wistar adult male rats (200 ± 50 g) were kept in Plexiglas cages with free access to food and water in a room with controlled temperature (22-23°C) and on a 12 h-light/dark cycle with lights on at 7:00 am. The experimental protocol of this study was approved by Animal Ethical Committee of Universidade Federal de Santa Maria (CIETEA-22/2010), which is affiliated to CONCEA, and was adhered to the ''Principles of Laboratory Animal Care'' (NIH publication) and international rules of ethics in research.
Preparation of haloperidol-loaded polysorbate-coated nanocapsules suspensions containing fish oil
Nanocapsules (H-NcFO) were prepared by interfacial deposition of preformed polymer, as described by Fessi et al. (1989) . Briefly, the organic solution consisted of FO (0.8 mL), poly(-caprolactone) (250 mg), haloperidol (6.3 mg), sorbitan monostearate (192 mg) and acetone (67 mL), which were poured under magnetic stirring into an aqueous solution (134 mL) containing polysorbate 80 (192 mg). Acetone was removed and the suspension concentrated by evaporation under reduced pressure. The final volume of the suspension was adjusted to 25 mL (0.25 mg/mL of haloperidol). Blank nanocapsules (B-NcFO) were prepared using the same protocol described above, but omitting the presence of the drug. Haloperidol free suspension (0.25 mg/mL) was prepared in an aqueous solution using 5% (w/v) of polysorbate 80.
Physicochemical characterization of nanocapsules
Particle sizes and polydispersity indices (n = 3) were measured by photon correlation spectroscopy after adequate dilution (1:500 v/v/) of an aliquot of the suspension in distilled water (Zetasizer Nanoseries ZEN 3600, Malvern Instruments, UK). Zeta potential was determined using the same equipment, but after dilution of the samples in 10 mmol L À1 NaCl aqueous solution. Drug content (mg/mL) was determined (n = 3) after dissolution of nanocapsules in acetonitrile (1 mL of suspension to 5 mL of acetonitrile) and assayed by high performance liquid chromatography (HPLC), according to previously described and validated protocol , using a Shimadzu instrument (LC-10AVP Pump, UV-VIS SPD-10AVP Module, Class-VP Software, Shimadzu, Tokyo, Japan). Encapsulation efficiency was determined by the ultrafiltration-centrifugation technique. So, the concentration of free drug was determined in the clear supernatant after this technique (Ultrafree-MC Ò 10,000 MW, Millipore, Bedford, USA). Encapsulation efficiency (%) was calculated by the difference between total and free drug concentrations determined in the nanocapsule suspension (drug content) and in the ultrafiltrate, respectively, using the HPLC method described above. pH values of suspensions were determined by immersion of the electrode directly in the suspension using a calibrated potentiometer (MPA-210 Model, MS-Tecnopon, São Paulo, Brazil), at room temperature. In addition, the morphological analysis was conducted by transmission electron microscopy (TEM; Jeol, JEM 1200 Exll, Centro de Microscopia Eletrônica, UFRGS) operating at 80 kV. For this analysis, the diluted suspension was deposited in Formvar-Carbon support film on specimen grid (electron microscopy sciences) and negatively stained with 2% (w/v) uranyl acetate solution.
In vivo experiments
2.5.1. Experiment 1: Motor side effects induced by acute haloperidol administration Twenty-eight rats were randomly divided in four groups (n = 7), and treated with single injection (ip) of aqueous solution containing polysorbate 80 5% (v/v) (negative control, group-C), haloperidol aqueous dispersion (free haloperidol, group-FH), blank nanocapsules (blank nanocapsules, group-B-NcFO) and haloperidol-loaded nanocapsules (haloperidol nanocapsules, group-H-NcFO). All suspensions were administered in the dose of 0.2 mg/kg-ip and the behavioral tests were performed one hour after the administration, according to the methodology described below: 2.5.1.1. Oral dyskinesia. Animals were individually placed in cages (20 Â 20 Â 19 cm 3 ) containing one mirror under the floor and one behind the back wall of the cage to allow behavioral quantification when the animal was facing away from the observer. To quantify the occurrence of oral dyskinesia, the incidence of vacuous chewing movement frequency (VCM) was recorded for three sets of 5 min with 5-min intervals. Observers were blind to the treatment. In a preliminary study (using five control and ten haloperidol-treated rats) of interrater reliability, we found that the use of this method of observation and definition for the parameters evaluated usually results in 94% agreement between three different observers.
2.5.1.2. Locomotor activity. In order to evaluate the reduction of haloperidol-induced motor activity, rats' spontaneous locomotor activity was quantified just after the first interval of oral dyskinesia. Animals were placed individually in the center of an open-field arena (40 Â 40 Â 30 cm) with black plywood walls and a white floor divided into nine equal squares, as described by Kerr et al. (2005) . The number of lines crossing and the number of rearings was recorded for 5 min. The crossing and rearing numbers were indicators of locomotor and exploratory activity, respectively. 2.5.1.3. Catalepsy time. This behavioral test was adapted from Rocha et al. (1997) . Catalepsy was measured using a wire grid (25 Â 9 Â 30 cm 2 ) inclined 45°relative to the bench top. This behavioral parameter is characterized by positional passivity, which is observed through failure to correct an uncomfortable imposed posture. Each rat was placed with its forepaws near the edge of the grid and the amount of time spent in this atypical position was recorded for three times, with an interval of 5 min between them. All the rats treated with haloperidol (group FH and group H-NcFO) were individually placed on the inclined grid and observed for 60 s. At the end of the three replications, the mean time spent by the rat without moving was calculated for each test.
Experiment 2:
Motor side effects induced by subchronic haloperidol administration and oxidative stress markers Twenty-eight rats were randomly divided in the same four groups (n = 7) described above (C, B-NcFO, FH and H-NcFO). All drugs were administered (ip) in the dose of 0.2 mg/kg/mL once a day, for 28 consecutive days. The same behavioral tests (oral dyskinesia, catalepsy time and locomotor activity) described above were performed 7, 14, 21, and 28 days after treatment initiation, immediately before administration of suspensions.
At day 29 animals were euthanized by cervical decapitation after anesthesia with sodium pentobarbital (50 mg/kg body weight-ip). Brains were removed and cut coronally at the caudal border of the olfactory tubercle. Cortex, hippocampus and striatum were removed; Posterior areas containing the right and left substantia nigra were carefully dissected according to the coordinates of the Atlas (Paxinos and Watson, 2007) : Anterior-posterior (AP) À4 to À6 mm; dorsal-ventral (DV) 7-8.8 mm; lateral (L) 2-3 mm, using external landmarks as delimiters of the region. Dissected nigral area, cortex, hippocampus and striatum were homogenized in 10v (w/v) of 0.1 M Tris-HCl, pH 7.4, centrifuged at 1300g (10 min) and the supernatants were used for OS biomarkers determination.
2.5.2.1. Lipid peroxidation measure. Lipid peroxidation (LP) was estimated by quantification of thiobarbituric acid reactive species (TBARS). LP was measured through the pink chromogen produced by the reaction of thiobarbituric acid with malondialdehyde (MDA) at 100°C, measured spectrophotometrically at 535 nm, according to Ohkawa et al. (1979) . Results were expressed as gmol MDA/g tissue.
2.5.2.2. Antioxidant defenses. Reduced gluthatione (GSH) tissue content was determined after reaction with 5,5 0 -dithiobis-(2-nitrobenzoic acid). The yellow color formed was read at 412 nm, according to Boyne and Ellman (1972) . A standard curve using cysteine was used to calculate the content of GSH in tissue samples, expressed as lmol GSH/g tissue.
Catalase (CAT) activity was spectrophotometrically quantified in tissues by the method of Aebi (1984) , which involves monitoring the disappearance of H 2 O 2 in the presence of cell homogenate (pH 7 at 25°C) at 240 nm. The enzymatic activity was expressed in lmol H 2 O 2 /min/g tissue.
Statistical analysis
Data were analyzed by two way ANOVA [(4 (FH/BNcFO/HNcFO/ C) Â 4 periods of behavioral quantifications)] followed by Duncan's multiple range test, when required. Pearson's correlation coefficient was calculated between behavioral parameters (VCM, catalepsy, crossing and rearing) and substantia nigra LP (TBARS levels). Data were analyzed using Statistica (11.0 version) and expressed as mean ± S.E.M. Significance was considered when p < 0.05.
Results
3.1. Physicochemical characteristics of polymeric nanocapsules are shown in Table 1 and Fig. 1 All formulations appeared macroscopically homogeneous and their aspects were similar to a milky bluish opalescent fluid (Tyndall effect). Both nanocapsule suspensions (B-NcFO and H-NcFO) presented particles in the submicrometric range (between 200 and 300 nm), low polydispersity (60.25), negative zeta potentials and neutral pH values (Table 1 ). The nanometric size population represents more than 97% of the particle size distribution for both formulations. Furthermore, H-Nc showed drug content of 0.249 mg/mL and excellent encapsulation efficiency (95.09 ± 0.43%). TEM analysis showed uniform and rounded particles (Fig. 1). 3.2. Motor side effects induced by haloperidol acute treatment (haloperidol-loaded nanocapsules or free haloperidol) are shown in Fig. 2 Oral dyskinesia: VCM frequency was increased by 310% after free haloperidol (FH) administration (p < 0.05) in relation to control (C group). Both nanocapsule suspensions (H-NcFO and B-NcFO groups) showed orofacial movements unchanged, which were similar to control (Fig. 2A) .
Catalepsy measurement: In this behavioral evaluation, C and BNcFO groups showed no catalepsy. Therefore, they were not included in the results and discussion sections. Duncan post hoc tests showed that H-NcFO treatment led to a decrease in immobility time (10%) in relation to FH group (p < 0.05) (Fig. 2B ).
Locomotor activity: Haloperidol-treated rats (FH and H-NcFO groups) demonstrated lower locomotor activity than C group. In fact, FH and H-NcFO groups presented a decrease of 86% and 84% in crossing and 90% and 84% in rearing, respectively ( Fig. 2C  and D) . Oral dyskinesia: Post hoc test showed a significant increase in VCM frequency in FH-treated group in relation to control (p < 0.05), while both nanocapsule suspensions (H-NcFO and BNcFO) did not affect this parameter in animals at all analyzed times (Fig. 3A) . Paired sample T-test indicated that vehicle-(C), blank nanocapsules-(B-NcFO) and free haloperidol-(FH) treated rats showed no changes in VCM frequency over time, but between days 7 and 14, haloperidol-loaded nanocapsules (H-NcFO) treatment increased this orofacial parameter.
Catalepsy time measurement: H-NcFO-treated rats showed lower immobility time than FH-treated onesat all analyzed times (p < 0.05) (Fig. 3B) . Paired sample T-test indicates that H-NcFO group increased catalepsy time at day 28 as compared to day 7.
Locomotor activity: FH-treated rats showed decreased crossing and rearing behavior at days 28 and 21, respectively, in relation to control. Both nanocapsule suspension (B-NcFO and H-NcFO) treatments did not affect locomotor activity in relation to control ( Fig. 4A and B) . Paired comparison indicates that FH group showed a significant decrease in crossing at days 21 and 28as compared to day 7and in rearing at days 21 and 28as compared to days 7 and 14.
3.4. Oxidative stress and antioxidant defenses parameters of rats treated with subchronic haloperidol treatment (haloperidol-loaded nanocapsules and free haloperidol) are shown in Table 2 Duncan post hoc test revealed that FH group showed an increase in TBARS levels in striatum and substantia nigra, a decrease in GSH levels in striatum and a reduction in CAT activity in substantia nigra as compared to C group. H-NcFO group showed a decrease in TBARS levels in striatum and substancia nigra as well as an increase in GSH levels in striatum in relation to FH group.
3.5. Correlations of rats treated with subchronic haloperidol (haloperidol-loaded nanocapsules containing fish oil and free haloperidol) are shown in Table 3 or Supplementary Figures 5 and 6 Pearson's correlation coefficient analyses revealed a significant positive correlation of substantia nigra TBARS levels with VCM frequency and catalepsy duration. In addition, there was a negative correlation of substantia nigra TBARS levels with locomotor parameters (crossing and rearing), confirming that haloperidol-induced motor disturbances are closely related to OS, verified through LP.
Discussion
Our previous study showed that antipsychotic effects of haloperidol-loaded nanocapsules was maintained for longer time and Fig. 3 . Subchronic effects of daily administration of free or nanoencapsulated haloperidol (0.2 mg/kg/mL-ip once a day, for 28 days) on vacuous chewing movement (VCM) frequency (A) and catalepsy time (B) in rats (n = 7). These observations were performed at 7, 14, 21 and 28 days after the first injection. C-control; B-NcFO-blank nanocapsules; FH-free haloperidol; H-NcFO-haloperidol-loaded nanocapsules. Data are expressed as mean ± S.E.M. (n = 7). Symbols indicate significant difference between treatments at same observed time:
⁄ difference from C group; + difference from FH group. Letters indicate significant difference between observed times in the same treatment: a difference from 7 day (p < 0.05 for all comparisons). more efficient and the motor side effects were reduced in relation to free haloperidol , but up to now no study had evaluated the oxidative status in extrapyramidal brain regions of rats treated with this formulation.
Many studies have demonstrated that drug-loaded nanocarriers are an efficient tool in drug delivery, enhancing therapeutic effects and reducing adverse side effects (Beck et al., 2005 (Beck et al., , 2006 Bernardi et al., 2009; Fontana et al., 2011; Wu et al., 2008) . Furthermore, these systems are able to promote permeation of drugs across the BBB, as previously demonstrated by several authors (Bernardi et al., 2009 Xin-Hua et al., 2011; Wang et al., 2009) , suggesting their use as an alternative to haloperidol delivery to the brain.
Here, haloperidol was efficiently encapsulated in polymeric nanocapsules using FO as oily core. The physicochemical properties of the new formulation are similar to the formulation previously developed using medium chain triglycerides as oil core . So, FO did not have any interference in the system, showing adequate nanotechnological characteristics (size, zeta potential, encapsulation efficiency and morphology) as well as drug delivery systems (pH and drug content). Although the zeta potential can be considered low (in module), it is important to highlight that these polymeric suspensions are stabilized by the presence of the polysorbate layer at the particle/water interface, acting as a steric stabilizer (Jager et al., 2007) .
Despite the advances observed in recent years, the mechanism involved in the transport of drug-loaded polymeric nanocapsule into the brain remains uncertain (Garcia-Garcia et al., 2005) . Polysorbate 80 could play a special role as anchor between nanoparticles and the apolipoprotein, especially ApoE. Nanoparticles combined with the apolipoprotein are considered as LDL, and LDL receptor-mediated transcytosis brings drug-loaded nanoparticles across the BBB (Kreuter et al., 2002) . In addition, polysorbate 80 could also inhibit the efflux system, especially P-glycoprotein (Kreuter, 2005) , which hinder the access of some drugs into the central nervous system. However, the exact mechanism involved in this transport remains unclear.
Motor side effects were monitored after acute and subchronic haloperidol treatment: Free haloperidol-treated group showed extrapyramidal side effects, evidenced by increase of OD frequency and catalepsy time, as well by locomotor impairment, reinforcing previous reports of our group (Barcelos et al., 2010; Colpo et al., 2007; Trevizol et al., 2011) and other research groups (Naidu et al., 2003; Zhang et al., 2007) .
Excitotoxicity and OS have been closely related to development of haloperidol-induced extrapyramidal side effects (Tsai et al., 1998) . In line with this, haloperidol administration can increase dopamine turnover, which reacts with molecular oxygen to form dopamine quinones depleting glutathione and generating reactive species during this process (Andreassen and Jorgensen, 2000) . In addition, blockade of striatal dopamine receptors can increase extracellular glutamate (Burger et al., 2005b) , which in turn contributes to OS development (Tsai et al., 1998) . Then, the Fig. 4 . Subchronic effects of daily administration of free or nanoencapsulated haloperidol (0.2 mg/kg/mL-ip once a day, for 28 days) on crossing (A) and rearing behavior (B) in rats (n = 7). These observations were performed at 7, 14, 21 and 28 days after the first injection. C-control; B-NcFO-blank nanocapsules; FH-free haloperidol; H-NcFOhaloperidol-loaded nanocapsules. Data are expressed as mean ± S.E.M. (n = 7). Symbols indicate significant difference between treatments at same observed time:
⁄ difference from C group; + difference from FH group. Letters indicate significant difference between observed times in the same treatment: a difference from day 7; b difference from day 14 (p < 0.05 for all comparisons).
involvement of excitotoxicity and particularly OS in haloperidolinduced motor disorders has been intensely studied by our group (Barcelos et al., 2010; Burger et al., 2005a,b; Colpo et al., 2007; Teixeira et al., 2011) seeking to better understand the pathophysiology of extrapyramidal disturbances induced by typical antipsychotics such as haloperidol, in order to minimize and/or prevent these symptoms. Of particular importance, findings of the present study demonstrated that free haloperidol administration caused a significant LP increase in striatum and substantia nigra, which are brain regions closely involved in movement disorders. Concomitantly, antioxidant defenses such as GSH levels and CAT activity were also reduced by free haloperidol treatment in striatum and substantia nigra, respectively. Contributing to our findings, a positive correlation between OD, locomotor activity and catalepsy with TBARS levels in the substantia nigra were observed, indicating a causal relationship between oxidative markers and extrapyramidal side effects. Such correlations reinforce the lower motor impairment induced by nanoencapsulated-haloperidol in relation to free drug. Taken together, these findings confirm OS involvement in development of extrapyramidal disorders such as haloperidol-induced OD. On the other hand, haloperidol loaded-nanocapsulescaused fewer motor side effects than free haloperidol did, with no significant increase of brain LP or changes in the antioxidant defense system. In fact, recently we showed that haloperidol nanocapsules was able to increase and prolong its antipsychotic action, which was accompanied of lower motor side effects , but until the time no study has compared the motor side effects induced by FH and HNcFO and their relationships with oxidative damages development in the extrapyramidal brain area. In fact, different preparations of slow release such as haloperidol decanoate and osmotic minipumps are currently available in the antipsychotic therapeutic arsenal, which achieve controlled release and stable plasma levels, but unfortunately, such formulations remain involved to the development of the long-term motor side effects. (Taylor, 2009; Andreassen and Jorgensen, 2000; Hyde et al., 1995) . In this sense, researches for new formulations that may minimize or delay the serious motor side effects induced by haloperidol are emerging. Here, we are showing for the first time that the beneficial effects of nanoencapsulated haloperidol on the motor system may result from lower oxidative damages in extrapyramidal brain regions, when compared to free drug. In fact, these brain structures themselves may be key contributors to OS development, mainly because they are rich in dopamine that generates reactive metabolites by autoxidation and deamination (by monoamino oxidase-MAO) (See, 1991) . Considering that haloperidol-loaded nanocapsules showed a more pronounced activity in a animal model of pseudo-psychosis and that drug-loaded polysorbate 80 coated-nanocapsules reach the brain more efficiently than the non-encapsulated drug (Bernardi et al., 2009; Frozza et al., 2010) , the hypothesis of lower delivery of haloperidol to the brain can be refuted. Thus, we can suggest two hypotheses: i) alteration in the distribution of haloperidol in the different brain areas to explain the decrease in the extrapyramidal motor disorders after administration of its nanoencapsulated form. This modified biodistribution could contribute to lower generation of reactive species and OS, evidenced here by minor LP in these dopaminergic regions; ii) haloperidol-loaded nanocapsules allow a sustained and continued delivery of drug, without causing its excessive bioaccumulation in brain extrapyramidal area, differently from FH, whose brain delivery occurs instantaneously and may generate a burst effect, facilitating drug accumulation in the same area of the basal ganglia, and evoking motor side effects, as shown in the present study. In seeking further information on this, some tests using HPLC were conducted recently in our laboratory in order to determine haloperidol brain levels (after free-and nanoencapsulatedhaloperidol treatment), but analytical condition was not sufficient to detect low levels of the drug in brain (lesser than 100 ng/mL), indicating inability and unreliability. Thus, there is a need to use a detector with higher sensitivity and establish new analytical conditions.
Furthermore, according to different authors, polymeric nanoparticles promote targeted drug delivery (Nagarwal et al., 2009; Zhu et al., 2009 ) and higher selectivity and lower systemic side effects (Beck et al., 2005 (Beck et al., , 2006 Gao et al., 2010) than the free drug. However, more studies involving both pharmacokinetic parameters such as biodistribution and tissue levels of haloperidol in brain dopaminergic areas are needed to confirm one or both the hypotheses proposed here.
Conclusion
Our study showed that haloperidol loaded-nanocapsules were able to minimize motor side effects as well as oxidative damages 
